Malignant Pleural Effusions: Management Options

Abstract

Malignant pleural effusion (MPE) represents advanced metastatic malignancy and is associated with poor median survival. Incidence remains high and continues to rise, in part due to changing population demographics. This therefore represents a significant health care burden. Management is predominantly palliative in nature and multiple interventions are available within conventional treatment paradigms, all of which are proven to result in statistically significant patient benefit. This article further explores the methods available in the management of MPE along with the pitfalls, complications, and alternatives. Recent advances within the field are discussed with an exploration of likely future directions, including the role of ultrasound as a prospective predictor and the role of intrapleural fibrinolytic therapy.

Keywords

malignant pleural effusion - talc pleurodesis - indwelling pleural catheter - palliative - care - unexpandable lung - autopleurodesis - thoracic ultrasound

• References

• 1 Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 (Suppl. 02) ii32-ii40
• 2 Clive AO, Kahan BC, Hooper CE. , et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014; 69 (12) 1098-1104
• 3 Psallidas I, Kanellakis NI, Gerry S. , et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol 2018; 19 (07) 930-939
• 4 Cancer Research UK. Worldwide Cancer Incidence Statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/incidence . Accessed August 2018
• 5 Cancer Research UK. Cancer Incidence Statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence . Accessed May 2018
• 6 Cancer Research UK. Mesothelioma Statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/mesothelioma . Accessed August 2018
• 7 Corcoran JP, Hallifax RJ, Talwar A, Psallidas I, Sykes A, Rahman NM. Intercostal chest drain insertion by general physicians: attitudes, experience and implications for training, service and patient safety. Postgrad Med J 2015; 91 (1075): 244-250
• 8 Davies HE, Mishra EK, Kahan BC. , et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012; 307 (22) 2383-2389
• 9 Thomas R, Fysh ETH, Smith NA. , et al. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA 2017; 318 (19) 1903-1912
• 10 Razazi K, Thille AW, Carteaux G. , et al. Effects of pleural effusion drainage on oxygenation, respiratory mechanics, and hemodynamics in mechanically ventilated patients. Ann Am Thorac Soc 2014; 11 (07) 1018-1024
• 11 Goligher EC, Leis JA, Fowler RA, Pinto R, Adhikari NK, Ferguson ND. Utility and safety of draining pleural effusions in mechanically ventilated patients: a systematic review and meta-analysis. Crit Care 2011; 15 (01) R46
• 12 Wang LM, Cherng JM, Wang JS. Improved lung function after thoracocentesis in patients with paradoxical movement of a hemidiaphragm secondary to a large pleural effusion. Respirology 2007; 12 (05) 719-723
• 13 Clive AO, Bhatnagar R, Psallidas I, Maskell NA. Individualised management of malignant pleural effusion. Lancet Respir Med 2015; 3 (07) 505-506
• 14 Havelock T, Teoh R, Laws D, Gleeson F. ; BTS Pleural Disease Guideline Group. Pleural procedures and thoracic ultrasound: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 (Suppl. 02) ii61-ii76
• 15 Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 2007; 84 (05) 1656-1661
• 16 Josephson T, Nordenskjold CA, Larsson J, Rosenberg LU, Kaijser M. Amount drained at ultrasound-guided thoracentesis and risk of pneumothorax. Acta Radiol 2009; 50 (01) 42-47
• 17 Psallidas I, Yousuf A, Talwar A. , et al. Assessment of patient-reported outcome measures in pleural interventions. BMJ Open Respir Res 2017; 4 (01) e000171
• 18 Lee YC, Light RW. Management of malignant pleural effusions. Respirology 2004; 9 (02) 148-156
• 19 Rahman NM, Pepperell J, Rehal S. , et al. Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial. JAMA 2015; 314 (24) 2641-2653
• 20 Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev 2016; (05) CD010529
• 21 Anderson CB, Philpott GW, Ferguson TB. The treatment of malignant pleural effusions. Cancer 1974; 33 (04) 916-922
• 22 Bhatnagar R, Laskawiec-Szkonter M, Piotrowska HEG. , et al. Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry (TAPPS trial): protocol of an open-label randomised controlled trial. BMJ Open 2014; 4 (11) e007045
• 23 Psallidas I, Piotrowska HEG, Yousuf A. , et al. Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE): protocol of a randomised controlled trial. BMJ Open Respir Res 2017; 4 (01) e000225
• 24 Zhu Z, Donnelly E, Dikensoy O. , et al. Efficacy of ultrasound in the diagnosis of pleurodesis in rabbits. Chest 2005; 128 (02) 934-939
• 25 Salamonsen MR, Lo AKC, Ng ACT, Bashirzadeh F, Wang WYS, Fielding DIK. Novel use of pleural ultrasound can identify malignant entrapped lung prior to effusion drainage. Chest 2014; 146 (05) 1286-1293
• 26 Corcoran JP, Talwar A, Hallifax RJ, Psallidas I, Wrightson JM, Rahman NM. P2 Incorporation of an in-depth thoracic ultrasound assessment into routine pre-procedural evaluation of patients with pleural effusions. Thorax 2016; 71 (Suppl. 03) A83-A4
• 27 Wahidi MM, Reddy C, Yarmus L. , et al. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP trial. Am J Respir Crit Care Med 2017; 195 (08) 1050-1057
• 28 Bhatnagar R, Keenan EK, Morley AJ. , et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med 2018; 378 (14) 1313-1322
• 29 Penz ED, Mishra EK, Davies HE, Manns BJ, Miller RF, Rahman NM. Comparing cost of indwelling pleural catheter vs talc pleurodesis for malignant pleural effusion. Chest 2014; 146 (04) 991-1000
• 30 Bhatnagar R, Corcoran JP, Maldonado F. , et al. Advanced medical interventions in pleural disease. Eur Respir Rev 2016; 25 (140) 199-213
• 31 Corcoran JP, Rahman NM. Picking the winners: outcome prediction in pleural disease. Respirology 2018; 23 (06) 558-559
• 32 Leemans J, Dooms C, Ninane V, Yserbyt J. Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: a single-centre experience. Respirology 2018; 23 (06) 613-617
• 33 Merrick C, Asciak R, Edey A, Maldonado F, Psallidas I. Pleural effusion. Eur Respir Monogr 2018; 79: 64-74
• 34 McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012; 186 (11) 1102-1108
• 35 Hollevoet K, Reitsma JB, Creaney J. , et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012; 30 (13) 1541-1549
• 36 Mishra EK, Clive AO, Wills GH. , et al. Randomized controlled trial of urokinase versus placebo for nondraining malignant pleural effusion. Am J Respir Crit Care Med 2018; 197 (04) 502-508
• 37 Rahman NM, Maskell NA, West A. , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365 (06) 518-526
• 38 Saydam O, Karapinar K, Gokce M. , et al. The palliative treatment with intrapleural streptokinase in patients with multiloculated malignant pleural effusion: a double-blind, placebo-controlled, randomized study. Med Oncol 2015; 32 (06) 612
• 39 Okur E, Baysungur V, Tezel C, Ergene G, Okur HK, Halezeroglu S. Streptokinase for malignant pleural effusions: a randomized controlled study. Asian Cardiovasc Thorac Ann 2011; 19 (3-4): 238-243
• 40 Davies CW, Traill ZC, Gleeson FV, Davies RJ. Intrapleural streptokinase in the management of malignant multiloculated pleural effusions. Chest 1999; 115 (03) 729-733
• 41 Bibby AC, Dorn P, Psallidas I. , et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J 2018; 52 (01) 52